Advice
following an abbreviated submission
atazanavir/cobicistat (Evotaz®) is accepted for use within NHS Scotland.
Indication under review: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.
Pharmacokinetic studies have demonstrated that atazanavir plus cobicistat is bioequivalent (in terms of atazanavir exposure) to ritonavir-boosted atazanavir.
For patients in whom atazanavir is an appropriate treatment, atazanavir/cobicistat (Evotaz®) provides a combination product at a small cost premium compared to ritonavir-boosted atazanavir.
Download detailed advice107KB (PDF)
Medicine details
- Medicine name:
- atazanavir & cobicistat (Evotaz)
- SMC ID:
- 1098/15
- Indication:
- In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 November 2015